ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1467

Health Related Quality of Life Is Reduced in Pediatric Patients with Juvenile Idiopathic Arthritis and Juvenile-Onset Fibromyalgia

Michal Feldon1, Catherine Donnelly2, Hermine I. Brunner3, Anne Louis Johnson1, Lukasz Itert4, Lisa G Rider5 and Edward H. Giannini3, 1Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Internal Medicine, University of Cincinnati, Cincinnati, OH, 3Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibromyalgia, juvenile idiopathic arthritis (JIA) and quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose : A
number of validated measures are now available for the evaluation of health
related quality of life (HRQOL) in children with rheumatic diseases, but most
are lengthy and not feasible for use in a clinical setting.

The objective of this study
was to document the degree of HRQOL impairment in juvenile idiopathic arthritis
(JIA) and juvenile-onset fibromyalgia (JFM) patients using the SF-10v2®
questionnaire.

Methods : Patients
ages 5-18 years with a diagnosis of JIA or JFM were recruited during routine
clinic visits in Cincinnati Children’s Hospital Medical Center (CCHMC) over 6
months. Demographic data as well as disease severity scores, including the physician’s
global, parental overall wellbeing and pain scores, were recorded from the
patients’ medical records. HRQOL was ascertained via the SF-10v2®
Health Survey questionnaire. The SF-10v2® is a 10-item caregiver-completed,
generic measure of children’s functional health and wellbeing over the
preceding 4 weeks; the SF10v2® features 2 summary measures – the
physical summary score [PHS] and the psychosocial summary score [PSS]. 

This was an exploratory,
cross-sectional descriptive study that examined the variation in HRQOL scores in
relation to different patient and disease characteristics, and compared the
scores of JIA and JFM patients to U.S age-and-gender-matched healthy and
physically ill children.

Results : 133
JIA and 9 JFM patients were included in the analysis. For JIA patients, mean
age at study entry and the mean duration of disease were 11.5 and 4.1 years,
respectively; 63% were female and 90% were Caucasian. All JFM patients were
Caucasian females with a mean age and mean duration of disease of 12.2 and 1
years, respectively.

Both summary scores of the SF-10v2®
were lower among JFM patients compared to JIA patients and to the age-and-gender-matched
healthy and physically ill populations. In contrast, the PHS only was lower for
JIA patients compared with the healthy and physically ill populations (Table 1).

Among the different JIA categories,
PHS scores for enthesitis-related arthritis (ERA) patients were lower than those
for polyarticular RF (-) JIA patients (31.72 vs. 45.31 p=0.018). For the JIA patients,
PHS scores were lower with active disease, abnormal parental scores and reported
pain. Age, gender, race, disease duration and additional autoimmune disease
were not associated with reduced scores (Table 2).

Conclusion :
HRQOL was lower among JIA and JFM patients compared to healthy and physically
ill children. Active disease and reported pain were the most important
predictors of reduced HRQOL among JIA patients.

Table 1: One-way ANOVA of HRQOL summary scores of JIA and JFM patients relative to age-and-gender-matched healthy and other physically ill U.S. children

 

Healthy*

Physically ill*

JIA

JFM

 

 

Tukey’s post-hoc analyses

 

N

Mean

(SD)

N

Mean

(SD)

N

Mean

(SD)

N

Mean

(SD)

F

P

 

PHS

1255

53.88

(5.2)

836

48.17

(11)

133

41.93

(14.83)

9

13.77

(11.84)

182

0.00

All comparisons were significant

PSS

54.61

(5.87)

53.1

(6.61)

53.61

(8.97)

42.77

(11.93)

18.61

0.00

Well vs. ill; Well vs. JFM;

Physically ill vs. JFM; JIA vs. JFM – P=0.00

Well vs. JIA and Physically ill vs. JIA – NS**

* The comparison populations were taken from a 2006 US general population sample with and without a parent-reported chronic condition, as provided by QualityMetric Inc.

**NS – non-significant

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Table 2: Comparisons of PHS and PSS in relation to different patient and disease characteristics among JIA patients

Variable

 

N

Physical summary score (PHS)

Psychosocial summary score (PSS)

 

 

 

Mean

(SD)

T-score

p-value

Mean

(SD)

T-score

p-value

Age

 

 

Age ≤ median

66

43.14

(15.24)

0.933

0.352

54.15

(8.83)

0.581

0.561

Age > median

67

40.74

(14.42)

53.24

(9.2)

Race

Caucasian

121

41.54

(15)

0.97

0.333

53.86

(9)

0.7

0.489

Non-Caucasian

12

45.87

(11.62)

51.95

(8.9)

Gender

Female

84

43.56

(14.44)

1.665

0.0982

53.77

(9.44)

0.129

0.897

Male

49

39.15

(15.22)

53.56

(8.28)

Duration of disease

Duration ≤ median

70

39.74

(15.5)

1.80

0.072

53.81

(8.4)

0.159

0.873

Duration > median

63

44.36

(13.69)

53.56

(9.67)

Autoimmune disease

Yes

27

43.47

(15.08)

0.6

0.548

46.24

(16.59)

0.77

0.439

No

106

41.54

(14.81)

50.31

(10.66)

Physician global score

<0.5

66

46.6

(12.02)

3.84

0.0002

53.36

(9.43)

0.16

0.872

≥0.5

57

36.9

(15.9)

53.63

(9.04)

Parental score

0

56

52.52

(5.15)

9.03

<0.0001

55.18

(6.07)

1.567

0.119

>0

68

33.68

(14.88)

52.68

(10.58)

Pain report

No pain

45

52.74

(5.45)

6.94

<0.0001

54.02

(6.94)

0.22

0.895

>0

86

36.45

(15.2)

53.66

(9.73)

 


Disclosure: M. Feldon, None; C. Donnelly, None; H. I. Brunner, None; A. L. Johnson, None; L. Itert, None; L. G. Rider, None; E. H. Giannini, None.

To cite this abstract in AMA style:

Feldon M, Donnelly C, Brunner HI, Johnson AL, Itert L, Rider LG, Giannini EH. Health Related Quality of Life Is Reduced in Pediatric Patients with Juvenile Idiopathic Arthritis and Juvenile-Onset Fibromyalgia [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/health-related-quality-of-life-is-reduced-in-pediatric-patients-with-juvenile-idiopathic-arthritis-and-juvenile-onset-fibromyalgia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-related-quality-of-life-is-reduced-in-pediatric-patients-with-juvenile-idiopathic-arthritis-and-juvenile-onset-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology